Zydus Lifesciences Ltd. benchmarking: Performance to industry peers

Financial

	Zydus Lifesciences	Mankind Pharma	Lupin
Operational Metrics
Pharmaceuticals
Number of ANDA's Filed in USA	505.0 .	67.0 .	430.0 .
Number of ANDA's Approved By USFDA	428.0 .	48.0 .	344.0 .
Domestic Sales Growth - YoY	12.0 %	9.8 %	11.2 %
US DMF Filings	147.0 .	n/a	94.0 .
R&D as a % of Total Sales	8.8 %	2.2 %	7.5 %
Financials
5 yr Average ROE	18.47 %	20.33 %	8.95 %
5yr average Equity Multiplier	1.52	1.46	1.73
5yr Average Asset Turnover Ratio	0.66	0.81	0.75
5yr Avg Net Profit Margin	19.02 %	17.68 %	5.06 %
Price to Book	4.02	6.76	4.63
P/E	20.6	58.09	19.5
5yr Avg Cash Conversion Cycle	-84.89 Days	-13.08 Days	-84.38 Days
Inventory Days	36.38 Days	59.06 Days	53.29 Days
Days Receivable	36.93 Days	34.35 Days	50.0 Days
Days Payable	160.15 Days	121.69 Days	160.27 Days
5yr Average Interest Coverage Ratio	30.19	46.07	6.26
5yr Avg ROCE	19.65 %	25.06 %	10.02 %
5yr Avg Operating Profit Margin	24.4 %	24.62 %	14.15 %
5 yr average Debt to Equity	0.17	0.16	0.3
5yr CAGR Net Profit	16.23 %	9.49 %	21.95 %
5yr Average Return on Assets	12.22 %	14.46 %	3.91 %
Shareholdings
Promoter Holding	75.0 %	72.66 %	46.86 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.02 %	-3.84 %	-0.22 %
Change in Mutual Fund Holding (3 Yrs)	-0.71 %	8.53 %	-0.03 %

Business

	Zydus Lifesciences	Mankind Pharma	Lupin
Product Wise Break-Up	Product Wise Break-Up US Formulations 41.0 India Formulations 25.0 Wellness 14.0 EMB Formulations 12.0 Active Pharmaceutical Ingredient (API) 3.0 Alliance 0.1 Emerging Markets 0 Europe Formulatios 0 Animal Health 0 Urology 0 Neuro/CNS 0 Pain/Analgesics 0 Gynaecology 0 Dermatology 0 Anti-Diabetic 0 Respiratory 0 VMN 0 Gastro - Intestinal 0 Cardiovascular 0 Anti-infectives 0 USA 0 Developed Markets 0 NCE licensing income 0 India 0 Emerging Market Formulation 0 Advanced Markets Formulations 0 Generic FDF 0 Custom Synthesis 0 Others 4.9	Product Wise Break-Up Neuro/CNS 2.0 Cardiovascular 16.0 India Formulations 0 Generic FDF 0 US Formulations 0 NCE licensing income 0 Pain/Analgesics 4.0 Anti-Diabetic 9.0 Developed Markets 0 Gynaecology 10.0 EMB Formulations 0 Emerging Market Formulation 0 Respiratory 9.0 Urology 5.0 Active Pharmaceutical Ingredient (API) 0 Dermatology 5.0 Europe Formulatios 0 Animal Health 0 India 0 USA 0 Gastrointestinal 9.0 Anti-infectives 13.0 Alliance 0 Emerging Markets 0 VMN 8.0 Wellness 0 Advanced Markets Formulations 0 Custom Synthesis 0 Others 10.0	Product Wise Break-Up Neuro/CNS 0 Cardiovascular 0 India Formulations 0 Generic FDF 0 US Formulations 0 NCD 1.0 Pain/Analgesics 0 Anti-Diabetic 0 Developed Markets 0 Gynaecology 0 EMB Formulations 0 Emerging Market 12.0 Respiratory 0 Urology 0 Active Pharmaceutical Ingredient (API) 0 Dermatology 0 Europe Formulatios 0 Animal Health 0 India 34.0 USA 0 Gastro - Intestinal 0 Anti-infectives 0 Alliance 0 Emerging Markets 0 VMN 0 Wellness 0 Advanced Markets Formulations 45.0 Custom Synthesis 0 Others 8.0
Segment Break-Up	Segment Break-Up Pharmaceuticals 85.95 OTC 14.05 Research Services & Sale of IP`s 0	-	Segment Break-Up OTC 0 Research Services & Sale of IP`s 0 Pharmaceuticals 99.48 Others 0.52
Location Wise Break-Up	Location Wise Break-Up USA 47.94 India 39.81 Nepal 0 Sri Lanka 0 Bangladesh 0 API 0 EMEA 0 Growth Markets 0 Japan 0 Others 12.25	Location Wise Break-Up Growth Markets 0 Bangladesh 0 Japan 0 India 85.0 EMEA 0 Nepal 0 USA 0 Sri Lanka 0 API 0 Others 15.0	Location Wise Break-Up Developed Markets 11.0 Bangladesh 0 Japan 0 India 29.0 EMEA 13.0 Nepal 0 USA 44.0 Sri Lanka 0 API 3.0
Operating Profit Break-Up	Operating Profit Break-Up Pharmaceuticals 100.0 Consumer Products 0	-	-
Therapeutic Area Break-Up	Therapeutic Area Break-Up Cardiac Science 18.0 Respiratory Systems 14.0 Anti-Infective 12.0 Oncology 9.0 Gastro Intestinal 9.0 Pain Management 8.0 Gynecology 7.0 Dermatology 6.0 Others 17.0	-	-
Asset Break-Up	Asset Break-Up India 93.18 USA 4.31 Others 2.51	-	-

Zydus Lifesciences Ltd.

Zydus Lifesciences Ltd.

Financial

Business

SIGN UP FOR FREE